{"disease":{"id":"amyloid","name":"amyloid"},"drugs":{"marketed":[{"drug_id":"daratumumab","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex","generic_name":"daratumumab","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"CD38","drug_class":"Monoclonal antibody","quality_score":10,"revenue":"11800","mechanism":"Daratumumab binds CD38 on tumor cells, inducing apoptosis and immune-mediated lysis via CDC, ADCC, and ADCP."},{"drug_id":"tafamidis","indication_name":"Amyloid polyneuropathy type I","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"tafamidis","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"tafamidis","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"tafamidis","indication_name":"Amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vutrisiran","indication_name":"Transthyretin familial amyloid polyneuropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amvuttra","generic_name":"VUTRISIRAN","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":10,"revenue":"1100","mechanism":"Amvuttra works by silencing the production of abnormal TTR protein through RNA interference."},{"drug_id":"cyclophosphamide","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"hyaluronidase","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wydase","generic_name":"HYALURONIDASE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"hyaluronic acid","drug_class":"Endoglycosidase","quality_score":10,"revenue":"900","mechanism":"Hyaluronidase increases tissue permeability by breaking down hyaluronic acid, promoting the diffusion and absorption of injected fluids."},{"drug_id":"patisiran-sodium","indication_name":"Transthyretin familial amyloid polyneuropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onpattro","generic_name":"PATISIRAN SODIUM","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":10,"revenue":"700","mechanism":"Onpattro works by silencing the production of abnormal TTR protein through RNA interference."},{"drug_id":"patisiran","indication_name":"Polyneuropathy in amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onpattro","generic_name":"PATISIRAN","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":59,"revenue":"700","mechanism":"Onpattro works by silencing the production of abnormal TTR protein using small interfering RNA."},{"drug_id":"patisiran","indication_name":"Transthyretin familial amyloid polyneuropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onpattro","generic_name":"PATISIRAN","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":59,"revenue":"700","mechanism":"Onpattro works by silencing the production of abnormal TTR protein using small interfering RNA."},{"drug_id":"patisiran-sodium","indication_name":"Polyneuropathy in amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onpattro","generic_name":"PATISIRAN SODIUM","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":10,"revenue":"700","mechanism":"Onpattro works by silencing the production of abnormal TTR protein through RNA interference."},{"drug_id":"dexamethasone","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Light Chain (AL) Amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"acetylcysteine","indication_name":"Amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetadote","generic_name":"Acetylcysteine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Glutathione levels; reactive metabolite of acetaminophen","drug_class":"Antidote","quality_score":62,"revenue":null,"mechanism":"Acetylcysteine reduces liver injury from acetaminophen overdose by maintaining glutathione levels or providing alternate conjugation substrate."},{"drug_id":"cyclophosphamid","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"acetylcystein","indication_name":"Amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Acetylcystein","company_name":"University Hospital, Strasbourg, France","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"velcade","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Velcade","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"26S proteasome non-ATPase regulatory subunit 1, PH and SEC7 domain-containing protein 1, Cathepsin G","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"bortezomib","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velcade","generic_name":"bortezomib","company_name":"Shilpa","drug_phase":"marketed","molecular_target":"26S proteasome chymotrypsin-like activity","drug_class":"Proteasome inhibitor","quality_score":76,"revenue":null,"mechanism":"Reversible inhibitor of 26S proteasome chymotrypsin-like activity preventing ubiquitinated protein degradation."},{"drug_id":"acoramidis","indication_name":"cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Attruby","generic_name":"ACORAMIDIS","company_name":"Bridgebio Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Attruby works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of amyloid conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"vyndamax","indication_name":"Amyloid polyneuropathy type I","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndamax","indication_name":"Amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndamax","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndamax","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Light Chain (AL) Amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"eplontersen","indication_name":"polyneuropathy of hereditary transthyretin-mediated amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wainua","generic_name":"EPLONTERSEN","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"","drug_class":"Transthyretin-directed RNA Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein."},{"drug_id":"cysteine","indication_name":"Amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cysteine Hydrochloride","generic_name":"CYSTEINE","company_name":"Exela Pharma","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Vitamin C [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1200796","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"darzalex","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Darzalex","company_name":"Shanghai Henlius Biotech","drug_phase":"marketed","molecular_target":"Lymphocyte differentiation antigen CD38","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"eplontersen","indication_name":"Polyneuropathy of hereditary transthyretin-mediated amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wainua","generic_name":"EPLONTERSEN","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"","drug_class":"Transthyretin-directed RNA Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein."},{"drug_id":"vyndaqel","indication_name":"Amyloid polyneuropathy type I","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"vyndaqel","indication_name":"Amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"vyndaqel","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"vyndaqel","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"18fflutemetamol","indication_name":"Amyloid Imaging","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(18F)Flutemetamol","generic_name":"18fflutemetamol","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"acetadote","indication_name":"Amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Acetadote","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tafamidis-test","indication_name":"Amyloid polyneuropathy type I","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"tafamidis-test","indication_name":"Amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"tafamidis-test","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"tafamidis-test","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."}],"pipeline":[{"drug_id":"vyndamax-tafamidis-61mg","indication_name":"ATTR-CM (Transthyretin Amyloid Cardiomyopathy)","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndamax (tafamidis 61mg)","generic_name":"vyndamax-tafamidis-61mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"As prescribed in real world practice","quality_score":0,"revenue":null,"mechanism":"As prescribed in real world practice"},{"drug_id":"treatment-for-ttr-amyloidosis","indication_name":"Transthyretin (TTR) Amyloid Cardiomyopathy","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment for TTR amyloidosis","generic_name":"treatment-for-ttr-amyloidosis","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if n","quality_score":null,"revenue":null,"mechanism":"The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if n"},{"drug_id":"tafamidis-61-milligrams","indication_name":"Transthyretin Amyloid Cardiomyopathy","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis 61 milligrams","generic_name":"tafamidis-61-milligrams","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Tafamidis 61mg as provided in real-world practice","quality_score":null,"revenue":null,"mechanism":"Tafamidis 61mg as provided in real-world practice"}],"offLabel":[],"totalMarketed":125,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT06355934","title":"OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis","phase":"","overall_status":"RECRUITING","enrollment_count":52121,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT05557162","title":"Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":20143,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06328075","title":"Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Algalarrondo Vincent","has_results":false},{"nct_id":"NCT00628745","title":"Transthyretin Amyloidosis Outcome Survey (THAOS)","phase":"","overall_status":"COMPLETED","enrollment_count":6718,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03237494","title":"TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects","phase":"","overall_status":"COMPLETED","enrollment_count":5028,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT05101304","title":"Registre HEAR, Healthcare European Amyloidosis Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Saving Lives Matters","has_results":false},{"nct_id":"NCT06748261","title":"AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05556928","title":"Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT04937777","title":"A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe","phase":"","overall_status":"COMPLETED","enrollment_count":4481,"lead_sponsor_name":"European Myeloma Network B.V.","has_results":false},{"nct_id":"NCT04915235","title":"Prevalence and Prognosis of Cardiac Amiloidosis in Turkey","phase":"","overall_status":"UNKNOWN","enrollment_count":2087,"lead_sponsor_name":"Turkish Society of Cardiology","has_results":false},{"nct_id":"NCT05283993","title":"A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT07358078","title":"DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT07235462","title":"A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06465810","title":"Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis","phase":"","overall_status":"RECRUITING","enrollment_count":1850,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06338839","title":"Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia","phase":"","overall_status":"TERMINATED","enrollment_count":1770,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02791230","title":"Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1733,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04561518","title":"ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT07207811","title":"CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1280,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT07052903","title":"TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1250,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04108091","title":"Vyndaqel Capsules Special Investigation (ATTR-CM)","phase":"","overall_status":"COMPLETED","enrollment_count":1214,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06183931","title":"Study of ALXN2220 Versus Placebo in Adults With ATTR-CM","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1181,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02114372","title":"Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":1136,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT07336394","title":"Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT04869631","title":"Screening for Amyloidosis Before Aortic Valve Elective Replacement","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT05593679","title":"A Multi-center Cardiac PYP Scan Registry in Taiwan","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Far Eastern Memorial Hospital","has_results":false},{"nct_id":"NCT05772091","title":"Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Pr. Nicolas GIRERD","has_results":false},{"nct_id":"NCT05444920","title":"The Italian Transthyretin Amyloidosis Web-Network","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT01164241","title":"Natural History of Severe Allergic Inflammation and Reactions","phase":"","overall_status":"COMPLETED","enrollment_count":945,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05734378","title":"Prognosis of Cerebral Small Vessel Disease","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT03842163","title":"Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology","phase":"","overall_status":"COMPLETED","enrollment_count":812,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07238426","title":"ATTRACT-52: Primary Care Cardiac Amyloidosis Screening in Ordu, Turkey","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":800,"lead_sponsor_name":"Kotyora Family Medicine Health Management and Education Association","has_results":false},{"nct_id":"NCT06383143","title":"Promoting Diagnosis and Management of AL in Italy (ProDigALIty)","phase":"","overall_status":"RECRUITING","enrollment_count":760,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT06414746","title":"Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia","phase":"","overall_status":"COMPLETED","enrollment_count":721,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06813443","title":"Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06679946","title":"A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":700,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04153149","title":"HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":655,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03812172","title":"Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations","phase":"","overall_status":"COMPLETED","enrollment_count":646,"lead_sponsor_name":"Mathew S. Maurer, MD","has_results":true},{"nct_id":"NCT06427304","title":"Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure","phase":"","overall_status":"RECRUITING","enrollment_count":637,"lead_sponsor_name":"Gérond'if","has_results":false},{"nct_id":"NCT03860935","title":"Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":632,"lead_sponsor_name":"Eidos Therapeutics, a BridgeBio company","has_results":true},{"nct_id":"NCT06836011","title":"A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT03029026","title":"The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.","phase":"","overall_status":"COMPLETED","enrollment_count":581,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT02569398","title":"An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":557,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT05064839","title":"Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":553,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT06998355","title":"BE.Amycon Registry UZ Leuven","phase":"","overall_status":"SUSPENDED","enrollment_count":550,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT06040567","title":"Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study","phase":"","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05577819","title":"Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF","phase":"NA","overall_status":"RECRUITING","enrollment_count":515,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT04204642","title":"SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","has_results":false},{"nct_id":"NCT02146378","title":"Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Pfizer","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}